Clinical Trial Update: Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis [Phase 4]

View source ↗

Summary

A Phase 4 study (PACE) evaluating physical activity in patients with relapsing-remitting multiple sclerosis treated with fingolimod was terminated, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Fatigue in Multiple Sclerosis | Phase 4 | Status: TERMINATED | Results posted: 2016-05-12